SCHEDULE: Trium Capital Exits Surmodics Stake

Trium Capital LLP has fully divested its entire stake in Surmodics Inc, reducing its beneficial ownership to zero percent.

Summary

• Trium Capital LLP, a UK-based investment adviser, has filed an Amendment No. 1 to its Schedule 13G regarding its holdings in Surmodics Inc.
• The filing indicates a complete exit from its position in Surmodics Inc's common stock.
• As of November 17, 2025, Trium Capital LLP beneficially owns 0% of Surmodics Inc's common stock.
• Trium Capital LLP no longer holds any sole or shared voting power, nor sole or shared dispositive power over Surmodics Inc shares.

Sentiment

Score: 3

Explanation: The complete divestment by Trium Capital LLP, an institutional investor, is generally perceived as a negative signal for Surmodics Inc, potentially indicating a lack of confidence or a strategic shift by the investor.

Negatives

• An institutional investor, Trium Capital LLP, has fully exited its position in Surmodics Inc.
• This divestment could be interpreted by the market as a lack of confidence or a strategic shift away from the company by this specific investor.

Risks

• The complete exit of an institutional investor could signal potential concerns about the company's future performance or valuation, potentially leading to negative market sentiment and downward pressure on the stock price.

Future Outlook

No forward-looking statements or guidance from Surmodics Inc are provided in this filing, as it is a disclosure from an institutional investor regarding its ownership change.

Industry Context

This filing reflects an investment decision by a specific fund, Trium Capital LLP, to fully divest its stake in Surmodics Inc. While the specific reasons are not disclosed, such an institutional exit could indicate a re-evaluation of Surmodics Inc's prospects within its industry (e.g., medical devices or diagnostics) or a broader shift in the investor's portfolio allocation.

Stakeholder Impact

• Shareholders: May react negatively to the news of an institutional investor exiting, potentially leading to downward pressure on the stock price.
• Management: May need to address market concerns if the exit is perceived as a vote of no confidence in the company's strategy or future performance.

Key Dates

Recommendation

The complete divestment by Trium Capital LLP, an institutional investor, signals a potential lack of confidence or a strategic re-allocation of capital. While not a definitive 'sell' signal on its own, it warrants a 'hold' recommendation for existing investors to re-evaluate their position and for potential investors to exercise caution and conduct further due diligence on Surmodics Inc's fundamentals and future prospects.

Keywords

Surmodics Inc, Trium Capital LLP, Schedule 13G, Institutional Ownership, Stock Divestment, Investment Adviser, Common Stock, Beneficial Ownership